Analyst Brendan Smith from TD Cowen maintained a Buy rating on Ginkgo Bioworks Holdings and keeping the price target at $12.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brendan Smith has given his Buy rating due to a combination of factors tied to Ginkgo Bioworks’ strategic refocus and improving efficiency. He views the completion of the biosecurity divestiture and the shift toward automation and data-generation as positioning the company for a more scalable, higher-quality revenue mix, even as near-term results reflect restructuring and program rationalization toward larger commercial customers.
He also highlights substantial operating expense reductions and reaffirmed guidance for materially lower cash burn by FY26 as evidence of disciplined cost control that extends the company’s financial runway. In addition, he sees the company’s selection for Benchling’s new marketplace, alongside AWS’ Bio Discovery platform, as opening incremental volume opportunities that can leverage Ginkgo’s automation strengths, supporting his unchanged $12 price target and Buy recommendation.